A light touch and an eye for detail have brought Ron Henriksen riches and adventure in a humble life of deal-making. And at
age 70, he has no plans to stop.
A panel of five leaders of the state’s life sciences
industry took on a wide range of topics
July 24 at IBJ’s Power Breakfast
at the Westin Indianapolis.
More emerging life science companies have found life in the form of federal
Small Business Innovation Research grants.
Midland, Mich.-based Dow Chemical Co. is still considering divesting Indianapolis subsidiary Dow AgroSciences LLC. But
chances that the chemical manufacturing giant will sell its local agricultural chemical and biotech unit appear to have decreased.
Investors in a company built around clinical research software bought from Eli Lilly and Co. have found their exit, though
it’s far from the lucrative payoff they’d once imagined.
Carmel-based Dormir LLC’s announcement July 29 of $12 million in venture financing was the second local life sciences
deal announced in July. It could suggest a turnaround from a woeful second-quarter performance, when Indiana life
sciences firms announced zero venture capital deals.
Eli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials
take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
Midland, Mich.-based Dow Chemical Co. is still considering divesting Indianapolis subsidiary Dow AgroSciences LLC. But chances
that the chemical manufacturing giant will sell its local agricultural chemical and biotech unit have decreased.
Indianapolis-based Dow AgroSciences LLC will have a new CEO after its parent organization moves Jerome Peribere into a new
position, the company announced today. Antonio Galindez, 54, vice president of Dow AgroSciences’ crops business, will step
into the top job.
Indianapolis-based Dow AgroSciences LLC will have a new CEO after its parent organization moves Jerome Peribere into a new
position, the company announced today.
Even after a string of acquisitions, Dow AgroSciences is a bit player in the seed business. But the new genetically
modified corn it developed with St. Louis-based giant Monsanto Co. finally provides the breakthrough product that could grow
its seed sales substantially.
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—low-cost and all over the world.
Favorable article in prestigious journal could draw attention to Carmel biotech startup.
Eli Lilly and Co.’s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales of
the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer
for certain patients, Lilly announced today.
The Indiana Minority Supplier Development Council has made life sciences companies its latest target—part of an even larger effort to attract minorities to the burgeoning life sciences industry under
way on a national scale.
West Lafayette-based life sciences contract research firm Bioanalytical Systems Inc. has five directors on its board. If company
founder Pete Kissinger has his way, four of them will soon be replaced.
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—a model that’s low-cost
and can spread around the world.
Ma quande lingues coalesce, t va semblar un simplificat Angles, quam un skeptic Cambridge amico dit me que Occidental es.
Compared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year,
Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
It took Pete and Candace Kissinger 33 years to build West Lafayette-based Bioanalytical Systems Inc. into one of the largest
contract research firms in Indiana’s life science sector. It took just a year and a half for them to turn against the company’s new management.
